Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 20;9(30):21613-21627.
doi: 10.18632/oncotarget.25085.

Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review

Affiliations
Review

Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review

Anjali V Sheahan et al. Oncotarget. .

Abstract

Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with unresectable (locally advanced or metastatic) tumors. We discuss a range of studies that employed FOLFIRINOX, the gemcitabine + nab-paclitaxel combination and studies that used molecularly-targeted therapy. Major areas of focus have been dual targeting of EGFR and VEGFR, immunotherapy or a multimodal approach - combining chemotherapy with radiotherapy. We also point out the need for molecular selection for low prevalence subtypes. Key insights sourced from these pivotal trials should improve clinical outcomes for this devastating cancer.

Keywords: bibliometric analysis; clinical trials; pancreatic cancer.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST AVB is in receipt of grants, honoraria and/or advisory board fees from MRC, Wellcome Trust, Cancer Research UK, Pancreatic Cancer UK, Chief Scientists Office of the Scottish Government, Pancreatic Cancer Action Network, Celgene, Clovis Oncology, Cure Forward, AstraZeneca, Elstar Therapeutics, Sagely Health and Abcodia. The other authors have no disclosure or conflicts of interest to declare.

Figures

Figure 1
Figure 1. Flow chart depicting how bibliometric information was processed in the course of this review
Figure 2
Figure 2. Proportion of studies in 2014-2016 that employed conventional chemotherapies
Gemcitabine- and fluoropyrimidine-based therapies were highly utilized in clinical trials, with increases seen in the employment of the latter over these 3 years. There were also increases in the utilization of the FOLFIRINOX and gemcitabine+nab-paclitaxel combinations in the same time period.
Figure 3
Figure 3. Proportion of studies in 2014-2016 that employed molecularly-targeted chemotherapies
Data is displayed in the order of the popularity of the target (the proportion of studies that utilized an inhibitor of that target). Molecularly targeted therapies were used in the majority of clinical trials investigating therapeutics in advanced pancreatic cancer patients in this timeframe.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30. - PubMed
    1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21. - PubMed
    1. Sheahan AV, Phillips PA, Khachigian LM. Therapeutic perspectives on pancreatic cancer. Curr Cancer Drug Targets. 2013;13:400–10. - PubMed
    1. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, et al. Groupe Tumeurs Digestives of Unicancer, and PRODIGE Intergroup FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25. - PubMed
    1. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703. - PMC - PubMed